News about "Julian Beach"

UK MHRA Approves Lurbinectedin for Extensive-Stage SCLC

The UK MHRA has approved lurbinectedin for adults with extensive-stage Small Cell Lung Cancer, with its safety and effectiveness to remain under close review.

Julian Beach | 25/09/2026 | By News Bureau

UK MHRA Approves Vimseltinib for Tenosynovial Giant Cell Tumours

UK MHRA approves Deciphera Pharma’s vimseltinib for adults with tenosynovial giant cell tumours affecting movement or where surgery is not an option.

Julian Beach | 18/08/2026 | By News Bureau

Jascayd (Nerandomilast) Wins UK MHRA Approval for Pulmonary Fibrosis Treatment

Nerandomilast (Jascayd) has been approved for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), expanding treatment options for these chronic lung diseases.

Julian Beach | 09/07/2026 | By News Bureau |  158

UK MHRA Approves Retifanlimab for Merkel Cell Skin Cancer

The UK MHRA has approved retifanlimab (ZYNYZ) for the treatment of advanced Merkel Cell Carcinoma (MCC), a rare and aggressive skin cancer with significant unmet medical need.

Julian Beach | 08/07/2026 | By Akanki |  137

Regulators Warn against Promotion of Newly Licensed Weight-Loss Medicines

MHRA, ASA, and GPhC have warned businesses against promoting newly licensed prescription-only and unlicensed weight-loss medicines, reinforcing compliance with advertising regulations and public health protections.

Julian Beach | 20/06/2026 | By News Bureau

UK MHRA Approves Vyjuvek for Treatment of Dystrophic Epidermolysis Bullosa Wounds

Medicines and Healthcare products Regulatory Agency has approved Vyjuvek for treating wounds in patients with dystrophic epidermolysis bullosa, including newborns.

Julian Beach | 18/05/2026 | By News Bureau |  184

MHRA Approves Olezarsen (Tryngolza) for Familial Chylomicronemia Syndrome

MHRA approves olezarsen (tryngolza) for adults with Familial Chylomicronemia Syndrome with subcutaneous injection administration.

Julian Beach | 13/04/2026 | By News Bureau |  177

MHRA Approves Bayer's Sevabertinib for HER2-Mutated Advanced Lung Cancer

Sevabertinib, a targeted therapy for HER2-mutated lung cancer, has been approved by the UK regulator to expand treatment options for advanced-stage patients.

Julian Beach | 04/04/2026 | By News Bureau |  196

MHRA Clears Deuruxolitinib (Leqselvi) by Sun Pharma for Severe Alopecia Areata in Adults

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved deuruxolitinib (Leqselvi) for treating severe Alopecia Areata in adults, granting authorisation to Sun Pharma UK via the International Recognition Procedure (IRP).

Julian Beach | 13/03/2026 | By News Bureau |  166

Medicines and Healthcare products Regulatory Agency Approves Inluriyo for Advanced ER-Positive Breast Cancer

The UK regulator has approved Inluriyo (imlunestrant tosylate) for adults with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations after prior hormone therapy failure.

Julian Beach | 26/02/2026 | By News Bureau |  240